(Z)-Nerolidol, commonly called cis-nerolidol, is the cis geometric isomer of nerolidol and appears in the AromaForge archive as a minor but real sesquiterpene alcohol component of folded mandarin oil. Compared with the broader nerolidol literature, direct cis-specific evidence is thinner but still usable: PubChem clearly distinguishes the isomer, and accessible studies report CYP-related metabolism effects, antiproliferative activity in cultured cancer cells, and some antimicrobial screening. Those data remain preclinical and often safety-relevant rather than consumer-benefit-ready, so this record should stay tightly evidence-led and avoid overclaiming.
Chemical identity and composition
PubChem maps cis-nerolidol to CID 5320128 with formula C15H26O, IUPAC name (6Z)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol, and a synonym list including cis-Nerolidol, (Z)-Nerolidol, Peruviol, and CAS 3790-78-1. In the local archive, exact Z-nerolidol naming is currently explicit in five-fold red mandarin concentrate at 1.08%. Much of the public nerolidol literature does not cleanly separate cis and trans isomers, so this profile leans on the smaller set of clearly cis-resolved papers.
Aroma and practical use
- Use the recorded floral, woody, fresh green, balsamic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2017 hepatocellular-carcinoma-cell study reported that only cis-nerolidol, not the compared nerolidol setup broadly, showed notable cytotoxic and antiproliferative activity in HepG2/C3A cells across the tested range, with G1 arrest and ER-stress-linked signaling changes.
The paper explicitly tied cis-nerolidol to mitochondrial membrane-potential changes, altered cyclin and CDK gene expression, and caspase-independent cell-death features.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2017 Molecules study found that cis-nerolidol, trans-nerolidol, and farnesol significantly inhibited CYP1A, CYP2B, and CYP3A activities in rat and human hepatic microsomes, while not significantly affecting the tested carbonyl-reducing or conjugation enzymes.
This is more relevant to interaction and safety framing than to benefit copy because it suggests plausible effects on concurrent xenobiotic metabolism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2015 antimicrobial screening paper included cis-nerolidol among the tested nerolidol derivatives against airborne microbes and plant-pathogenic fungi, but the abstract did not identify cis-nerolidol as the strongest performer in that set.
This supports biological activity screening interest but also underscores that cis-nerolidol was not the standout antimicrobial in that particular comparison.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The clearest cis-specific safety-relevant signal in this pass was CYP inhibition in rat and human hepatic microsomes, so interaction-aware wording is more defensible than broad wellness copy.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No human clinical efficacy or tolerability study specific to isolated (Z)-nerolidol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because much of the broader nerolidol literature mixes cis and trans forms, claims should stay explicitly tied to cis-resolved studies where possible.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
induction of endoplasmic-reticulum-stress-linked antiproliferative responses
The HepG2/C3A study linked cis-nerolidol with altered mitochondrial membrane potential, G1 arrest, ER-stress markers such as EIF2AK3 and ERN1, and caspase-independent cell death features.
This experimental finding does not establish benefit, dose or safety in people using this blend.
inhibition of selected CYP-mediated xenobiotic metabolism
A 2017 study in rat and human hepatic subcellular fractions reported inhibition of CYP1A, CYP2B, and CYP3A activities by cis-nerolidol and related sesquiterpenes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a human clinical trial specific to isolated cis-(Z)-nerolidol.
- Public safety literature is much stronger for mixed-isomer nerolidol than for the cis isomer alone.
- Archive occurrence is currently narrow, so the profile is supported more by isomer-specific chemistry and preclinical studies than by broad in-archive prevalence.
- No IFRA standard, RIFM monograph, or Tisserand & Young dermal limit specific to cis-(Z)-nerolidol was located; the previous dermal_limit_pct (20%) and sensitizing/phototoxic flags had no supporting citation and have been cleared pending verified data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.